Nieuws

jun
20

Alzheimer's Drug Discovery Foundation - Preclinical Drug Discovery RFP 2016

The Alzheimer's Drug Discovery Foundation (ADDF) invites applications for the Preclinical Drug Discovery funding mechanisms. The upcoming deadline for the submission of a Letter of Intent is August 12, 2016. Funding can range from $ 150,000 and $ 600,000 per year depending on the stage of research and must be justified based on the scientific work plan. In some cases, multi-year proposals can be considered.The funding mechanisms are the following:

Academic Program seeks to create and support innovative translational programs in academic medical centers and universities;
Biotechnology Program helps to create new biotechnology companies, and to fund existing biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. Funding is provided through program-related investments (PRIs) that require return on investment based upon scientific and/or business milestones.

The 2016 Preclinical research funding priorities are:

Drug Discovery - Target validation, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization-, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics;
Biomarker Development - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.

ADDF funds drug discovery research programmes from investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.

Terug naar overzicht